The DEA’s COVID-era telemedicine prescribing flexibilities allowed providers to prescribe controlled substances via telemedicine without an in-person exam. With permanent rules now in place, the landscape has changed.
What the permanent rules establish
The DEA’s telemedicine prescribing rules create a framework for prescribing Schedule III-V controlled substances via telemedicine following an audio-video encounter. Schedule II substances face stricter requirements and in most cases still require an in-person exam for initial prescribing.
The telemedicine registry
The permanent rules establish a DEA telemedicine registry for prescribers who want to prescribe controlled substances via telemedicine. This is separate from the standard DEA registration. Pharmacists should be aware that prescriptions from telemedicine encounters may have different documentation requirements.
What pharmacists should verify
When dispensing controlled substances prescribed via telemedicine: confirm the prescriber has appropriate DEA registration, verify the prescription meets state requirements for telemedicine prescriptions, and document appropriately.
Buprenorphine
The rules include specific provisions for buprenorphine for opioid use disorder. Pharmacists dispensing buprenorphine prescribed via telemedicine should be familiar with both federal and state-specific requirements. Always verify current requirements directly with DEA and your state board.